CD274 and cancer: A comprehensive meta‐analysis assessing the benefit of PD‐1/PD‐L1 therapy in cancer patients has shown the response rates typically fall in the range from 10% to 30% in various carcinogen‐induced solid tumours including those affecting the liver, bladder and kidneys.15